Molecular Partners to Present at Inaugural UBS Global Biopharma Conference
Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026
Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors
Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
After Plunging 18.3% in 4 Weeks, Here's Why the Trend Might Reverse for Molecular Partners AG Sponsored ADR (MOLN)
Molecular Partners Q3 EPS $(0.38) Beats $(0.46) Estimate
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
Molecular Partners Reports Nine Active Trial Sites And Ongoing Treatment In Phase 2 MP0317 Cholangiocarcinoma Study, With Data Update Expected In 2027 And Completion In 2028
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
Molecular Partners Highlights Multispecific Radio-DARPins Formatted As Bispecific Or 2-In-1 DuoDARPin To Address Tumor Heterogeneity
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
Molecular Partners Updates Pipeline As MP0712 Dosing Continues, NuMeRI Initiates Compassionate Care With 225Ac DLL3 Radio-DARPin, And MP0726 Imaging Targeted For Second Half Of 2026
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
Molecular Partners And Orano Med Dose First Patients In DLL3-Targeting Radio-DARPin Small Cell Lung Cancer Study
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.